Goldsmith Petra M, Bottomley Matthew J, Okechukwu Okidi, Ross Victoria C, Ghita Ryan, Wandless David, Falconer Stuart J, Papachristos Stavros, Nash Philip, Androshchuk Vitaliy, Clancy Marc
Renal Transplant Unit, Royal Liverpool University Hospitals NHS Trust, Liverpool, UK.
Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
BMJ Open. 2017 Jul 28;7(7):e016144. doi: 10.1136/bmjopen-2017-016144.
High intrapatient variability (IPV) in tacrolimus trough levels has been shown to be associated with higher rates of renal transplant failure. There is no consensus on what level of IPV constitutes a risk of graft loss. The establishment of such a threshold could help to guide clinicians in identifying at-risk patients to receive targeted interventions to improve IPV and thus outcomes.
A multicentre Transplant Audit Collaborative has been established to conduct a retrospective study examining tacrolimus IPV and renal transplant outcomes. Patients in receipt of a renal transplant at participating centres between 2009 and 2014 and fulfilling the inclusion criteria will be included in the study. The aim is to recruit a minimum of 1600 patients with follow-up spanning at least 2 years in order to determine a threshold IPV above which a renal transplant recipient would be considered at increased risk of graft loss. The study also aims to determine any national or regional trends in IPV and any demographic associations.
Consent will not be sought from patients whose data are used in this study as no additional procedures or information will be required from participants beyond that which would normally take place as part of clinical care. The study will be registered locally in each participating centre in line with local research and development protocols. It is anticipated that the results of this audit will be disseminated locally, in participating NHS Trusts, through national and international meetings and publications in peer-reviewed journals.
他克莫司谷浓度的患者内高变异性(IPV)已被证明与肾移植失败率较高相关。对于何种IPV水平构成移植物丢失风险尚无共识。确定这样一个阈值有助于指导临床医生识别有风险的患者,以便进行有针对性的干预,从而改善IPV并进而改善治疗结果。
已成立一个多中心移植审计协作组,以开展一项回顾性研究,检查他克莫司IPV和肾移植结果。2009年至2014年期间在参与中心接受肾移植且符合纳入标准的患者将被纳入研究。目标是招募至少1600名患者,随访至少2年,以确定一个IPV阈值,高于该阈值的肾移植受者将被视为移植物丢失风险增加。该研究还旨在确定IPV的任何国家或地区趋势以及任何人口统计学关联。
本研究使用其数据的患者无需寻求同意,因为除了作为临床护理常规部分通常会进行的程序或信息外,不会要求参与者提供额外的程序或信息。该研究将根据当地的研究与发展方案在每个参与中心进行本地注册。预计本次审计的结果将在当地、参与的国民保健服务信托机构、通过国家和国际会议以及在同行评审期刊上发表进行传播。